OUR FREE LIVE REAL WORLD MASTERCLASS SERIES WILL BE BACK AFTER THE SUMMER
‘How to ensure success and avoid pitfalls in Real World studies by Understanding Healthcare in Europe and Asia’
Dates: Restarting in September 2023 | Time: 5pm CET | 4pm UK | 11am EST | 8am PST
OXON will be resuming the series of masterclasses on real world evidence after the summer
This Masterclass series follows the successful Masterclasses in 2021on real-world studies and RCTs by OXON and the eminent statistician, Stuart Pocock, Professor of Medical Statistics, London School of Hygiene & Tropical Medicine (devised: ‘Pocock Stopping Rule’, ‘Win Ratio’. ‘Individualising benefit-risk’); extensive experience with EMA/FDA and data monitoring committees (including adaptive platform Covid-19 DISCOVERY trial); >500 publications (100+ NEJM/Lancets) mainly of trials and epidemiology.
The series provides practical knowledge and advice from national academic experts to apply to field, secondary data and hybrid observational studies for safety, HEOR/market access and clinical development. It is aimed at professionals in the biopharmaceutical and medical device industries, anywhere in the world, involved in the production of real-world evidence and conduct of observational studies in Europe and Asia.
UPCOMING MASTERCLASSES CALENDAR
| Title | Date | Start Time | Duration | Register |
|---|---|---|---|---|
| WEBINAR SERIES ON RWE: Session 2 - Designing & Delivering Successful RWE Across Japan Part of the OXON Webinar Series on RWE 2026–2027, this live session with Prof. Masao Iwagami will provide practical, country-specific insights into Japan’s healthcare system and the major real-world data sources available to support the design and delivery of high-quality RWE studies. Attendees will gain a clearer understanding of the opportunities and challenges of conducting RWE in Japan, including key considerations related to healthcare structure, clinical practice, and database selection. | 24 Jun, 2026 | 17:00 CEST | 1 hour | Register |
| WEBINAR SERIES ON RWE: Session 3 - Designing & Delivering RWE in Vaccines Part of the OXON Webinar Series on RWE 2026–2027, this live session on Real-World Evidence in Vaccines will provide practical insights into how real-world data can support vaccine research, evidence generation and decision-making. Attendees will gain a clearer understanding of the opportunities and challenges of conducting RWE studies in vaccines, including key considerations related to vaccine effectiveness, safety, uptake, impact and study design in routine clinical practice. | 16 Sep, 2026 | 17:00 CEST | 1 hour | Register |
| WEBINAR SERIES ON RWE: Session 4 - Designing & Delivering Successful RWE Across the UK Part of the OXON Webinar Series on RWE 2026–2027, this live session with Prof. Thomas MacDonald will provide practical, country-specific insights into the UK healthcare system and the major real-world data sources available to support the design and delivery of high-quality RWE studies. Attendees will gain a clearer understanding of the opportunities and challenges of conducting RWE in the UK, including key considerations related to healthcare structure, clinical practice, and database selection. | 18 Nov, 2026 | 17:00 CET | 1 hour | Register |
About OXON’s Free Live Masterclass Series on RW Studies
These are masterclass sessions to understand the healthcare for RW studies, led by leading professors of pharmacoepidemiology in Europe and Asia, centred on the practical theme of “How to ensure success of your RWE studies and avoid pitfalls”
The series are delivered by leading native pharmacoepidemiologists together with OXON, and are centred on understanding healthcare and data sources to fulfil RW field and secondary data studies in their various countries.
The remaining sessions will review specific topics, such as:
- How to ensure success of your RWE studies and avoid pitfalls in South Korea
- How to ensure success of your RWE studies and avoid pitfalls in Taiwan
- How to ensure success of your RWE studies and avoid pitfalls in Spain
- External Control Groups for Regulatory and HTA submissions
- Multi-country RW Data Collection Studies
- Multi-Country RW Secondary Data Studies